Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.35 |
| ▸ | RAF1 | P04049 | 7/20 | 0.35 |
| ▸ | KRAS | P01116 | 6/20 | 0.35 |
| ▸ | KDR | P35968 | 6/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.35 |
| ▸ | ARAF | P10398 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521649 | 0.93 | BRAF (0.36) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521957 | 0.93 | BRAF (0.37) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521597 | 0.89 | BRAF (0.36) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521616 | 0.87 | BRAF (0.37) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521530 | 0.87 | FGFR4 (0.40) | FGFR4 | |
| SCHEMBL1521499 | 0.86 | BRAF (0.47) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521978 | 0.84 | RAF1 (0.33) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521824 | 0.83 | RAF1 (0.33) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521774 | 0.81 | RAF1 (0.33) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL1521857 | 0.81 | ATR (0.33) | BRAFRAF1KRASKDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | claimed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | claimed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | claimed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | BRAF 1/4885RAF1 3/4885KRAS 30/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | BRAF 1/4885RAF1 3/4885KRAS 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.